Newsletter

207940 - Samsung Biologics Co., Ltd.

207940 Summary
Biopharma
Stock Price & Overview
₩1,447,000 -30,000 (-2.03%) Close · Sep 4, 2026 KST
KOSPI | ₩KRW | Close: ₩1,447,000  ≈ US$1,034  ·  Market cap ₩67.0tn (≈ $47.8bn)
Why this page exists. Korean issuers file to DART, not the SEC, and almost nothing is published in English. Titles here are translated; where kstock has read the filing, the row carries the explanation and the amount in won and dollars. How we pick »

207940 DART Filings

DART

Acquisition of Shares in Another Company

M&A08/31/26title translated
DART

Large business group status disclosure — quarterly, individual company

Filing08/31/26title translated
DART

Material event report (paid-in capital increase)

Filing08/28/26title translated
DART

Record date set, shareholder register closed

Filing08/28/26title translated
DART

Securities registration statement (equity securities)

Filing08/28/26title translated
DART

Material event report (acquisition of shares in another company)

Filing08/28/26title translated
DART

Half-Year Report

Periodic08/14/26title translated
DART

Supplier Payment Terms and Dispute-Resolution Disclosure

Governance08/14/26title translated
DART

Preliminary Consolidated Results (Fair Disclosure)

Earnings07/23/26title translated
DART

Material event report (acquisition of shares in another company)

Filing07/20/26title translated
DART

Advance notice of results disclosure (notice)

Filing07/09/26title translated
DART

Single Supply Contract Signed

Contract06/22/26title translated
DART

Single Supply Contract Signed

Contract06/17/26title translated
DART

Single Supply Contract Signed

Contract06/09/26title translated
DART

Sustainability report (voluntary)

Filing06/01/26title translated
DART

Capital Contribution to a Related Party

Related party06/01/26title translated
DART

Large business group status disclosure — annual and Q1, individual company

Filing06/01/26title translated
DART

Corporate governance report

Filing06/01/26title translated
DART

Quarterly Report

Periodic05/15/26title translated
DART

Annual Report

Periodic05/15/26title translated
9 routine filings (insider holdings reports, IR schedules)DART

Investor Relations Event

IR09/03/26title translated
DART

Investor Relations Event

IR08/28/26title translated
DART

Insider / Major Shareholder Holdings Report

Ownership08/06/26title translated
DART

Change in the Largest Shareholder's Holdings

Ownership08/03/26title translated
DART

5% Ownership Report — Short Form

Ownership07/31/26title translated
DART

Change in the Largest Shareholder's Holdings

Ownership07/06/26title translated
DART

Change in the Largest Shareholder's Holdings

Ownership06/01/26title translated
DART

Insider / Major Shareholder Holdings Report

Ownership05/20/26title translated
DART

Change in the Largest Shareholder's Holdings

Ownership05/04/26title translated
29 filings on file, grouped where one event produced many. Source: DART, operated by Korea's Financial Supervisory Service.

Similar to 207940

SymbolLast Price
068270Celltrion, Inc.₩188,100
+0.5%
196170Alteogen Inc.₩288,500
+1.9%
326030SK biopharmaceuticals Co., Ltd.₩86,600
+0.2%
128940Hanmi Pharm. Co., Ltd.₩473,500
+2.8%
000100Yuhan Corporation₩81,400
+0.0%
028300HLB Co., Ltd.₩33,750
+2.9%
298380ABL Bio Inc.₩71,400
+5.6%
000250Samchundang Pharm₩157,000
+1.0%
087010Peptron, Inc.₩157,300
+7.3%
141080LigaChem Biosciences Inc.₩92,000
+4.2%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.